Owlstone Medical, a global leader in Breath Biopsy for early disease detection and precision medicine, has announced a funding to the tune of $6.5 million.
Achaogen sells majority of assets for a grand total of $16m ahead of bankruptcy, in another indication of the difficulties of relying on antibiotics for revenue.